Carbenoxolone

Jump to: navigation, search
Carbenoxolone
Skeletal formula of carbenoxolone
Ball-and-stick model of the carbenoxolone molecule
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC34H50O7
Molar mass570.765 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Carbenoxolone

Articles

Most recent articles on Carbenoxolone

Most cited articles on Carbenoxolone

Review articles on Carbenoxolone

Articles on Carbenoxolone in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Carbenoxolone

Images of Carbenoxolone

Photos of Carbenoxolone

Podcasts & MP3s on Carbenoxolone

Videos on Carbenoxolone

Evidence Based Medicine

Cochrane Collaboration on Carbenoxolone

Bandolier on Carbenoxolone

TRIP on Carbenoxolone

Clinical Trials

Ongoing Trials on Carbenoxolone at Clinical Trials.gov

Trial results on Carbenoxolone

Clinical Trials on Carbenoxolone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Carbenoxolone

NICE Guidance on Carbenoxolone

NHS PRODIGY Guidance

FDA on Carbenoxolone

CDC on Carbenoxolone

Books

Books on Carbenoxolone

News

Carbenoxolone in the news

Be alerted to news on Carbenoxolone

News trends on Carbenoxolone

Commentary

Blogs on Carbenoxolone

Definitions

Definitions of Carbenoxolone

Patient Resources / Community

Patient resources on Carbenoxolone

Discussion groups on Carbenoxolone

Patient Handouts on Carbenoxolone

Directions to Hospitals Treating Carbenoxolone

Risk calculators and risk factors for Carbenoxolone

Healthcare Provider Resources

Symptoms of Carbenoxolone

Causes & Risk Factors for Carbenoxolone

Diagnostic studies for Carbenoxolone

Treatment of Carbenoxolone

Continuing Medical Education (CME)

CME Programs on Carbenoxolone

International

Carbenoxolone en Espanol

Carbenoxolone en Francais

Business

Carbenoxolone in the Marketplace

Patents on Carbenoxolone

Experimental / Informatics

List of terms related to Carbenoxolone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Carbenoxolone (CBX) is a glycyrrhetinic acid derivative with a steroid-like structure, similar to substances found in the root of the licorice plant. Carbenoxolone is used for the treatment of peptic, esophageal and oral ulceration and inflammation. Electrolyte imbalance is a serious side effect of carbenoxolone when used systemically.[1]

Carbenoxolone reversibly inhibits the conversion of cortisol to the inactive metabolite cortisone by blocking 11β-hydroxysteroid dehydrogenase (11β-HSD). 11β-HSD also reversibly catalyzes the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. [2][3]

Carbenoxolone is a modestly potent, reasonably effective, water-soluble blocker of gap junctions.[4]

Nootropic effects

Carbenoxolone has also been investigated for nootropic effects.[5] This research started from an observation that long-term exposure to glucocorticoids may have negative effects on cognition. Carbenoxolone may decrease the amount of active glucocortocoid in the brain, because the drug inhibits 11β-HSD, an enzyme which regenerates cortisol, an active glucocorticoid, from inactive cortisone.

In the research trial investigating this use of carbenoloxone, it was shown that the drug improved verbal fluency in elderly healthy men (aged 55–75). In type 2 diabetics aged 52–70, the drug improved verbal memory. However, potassium-sparing diuretic amiloride was co-administered with carbenoxolone, since carbenoxolone used by itself may cause hypertension by increasing cortisol in the kidneys.

References

  1. "Tales of a Dirty Drug: Carbenoxolone, Gap Junctions, and Seizures".
  2. "PubChem Compound".
  3. "Sigma-Aldrich" (PDF).
  4. "Tales of a Dirty Drug: Carbenoxolone, Gap Junctions, and Seizures".
  5. Sandeep TC, Yau JL, MacLullich AM; et al. (2004). "11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics". Proc. Natl. Acad. Sci. U.S.A. 101 (17): 6734–9. doi:10.1073/pnas.0306996101. PMC 404114. PMID 15071189.



Linked-in.jpg